Marshall Wace North America L.P. Decreases Holdings in Inogen Inc (NASDAQ:INGN)

Marshall Wace North America L.P. reduced its stake in shares of Inogen Inc (NASDAQ:INGN) by 70.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,141 shares of the medical technology company’s stock after selling 12,378 shares during the period. Marshall Wace North America L.P.’s holdings in Inogen were worth $490,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of INGN. BlackRock Inc. boosted its holdings in Inogen by 4.4% in the fourth quarter. BlackRock Inc. now owns 2,233,303 shares of the medical technology company’s stock worth $277,307,000 after purchasing an additional 93,873 shares in the last quarter. William Blair Investment Management LLC raised its position in shares of Inogen by 62.2% during the first quarter. William Blair Investment Management LLC now owns 1,048,413 shares of the medical technology company’s stock valued at $99,987,000 after buying an additional 402,150 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Inogen by 15,943.5% during the first quarter. Janus Henderson Group PLC now owns 552,056 shares of the medical technology company’s stock valued at $52,650,000 after buying an additional 548,615 shares during the last quarter. Norges Bank acquired a new position in shares of Inogen during the fourth quarter valued at about $48,104,000. Finally, New York State Common Retirement Fund raised its position in shares of Inogen by 19.7% during the first quarter. New York State Common Retirement Fund now owns 368,575 shares of the medical technology company’s stock valued at $35,151,000 after buying an additional 60,701 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Inogen stock traded down $0.08 during trading hours on Thursday, hitting $59.81. 376,939 shares of the stock were exchanged, compared to its average volume of 573,157. Inogen Inc has a 12 month low of $58.43 and a 12 month high of $287.79. The company has a quick ratio of 6.70, a current ratio of 7.35 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average of $65.89. The stock has a market capitalization of $1.31 billion, a PE ratio of 26.00, a P/E/G ratio of 2.45 and a beta of 1.45.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, May 7th. The medical technology company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.05). The business had revenue of $90.20 million during the quarter, compared to the consensus estimate of $89.69 million. Inogen had a net margin of 12.56% and a return on equity of 15.59%. Inogen’s revenue was up 14.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.48 earnings per share. As a group, sell-side analysts expect that Inogen Inc will post 1.63 EPS for the current year.

A number of brokerages have recently commented on INGN. BidaskClub lowered shares of Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, June 27th. Needham & Company LLC raised shares of Smart Global from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a research report on Friday, June 28th. Stifel Nicolaus raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and increased their price target for the stock from $11.00 to $17.00 in a research report on Wednesday, May 8th. Finally, JPMorgan Chase & Co. increased their price target on shares of from GBX 385 ($5.03) to GBX 480 ($6.27) and gave the stock an “overweight” rating in a research report on Wednesday, July 3rd. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Inogen currently has an average rating of “Hold” and a consensus price target of $117.60.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Recommended Story: Price to Earnings Ratio (PE)

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.